Last reviewed · How we verify
Sihuan Pharmaceutical Holdings Group Ltd. — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
2 Phase 3
2 Phase 2
5 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Anaprazole Sodium enteric-coated tablet | Anaprazole Sodium enteric-coated tablet | marketed | ||||
| Placebo/Janagliflozin | Placebo/Janagliflozin | phase 3 | SGLT2 inhibitor | SGLT2 (sodium-glucose cotransporter 2) | Diabetes | |
| Janagliflozin plus metformin | Janagliflozin plus metformin | phase 3 | SGLT2 inhibitor + biguanide combination | SGLT2; metformin (mitochondrial complex I) | Diabetes |
Therapeutic area mix
- Diabetes · 2
- Other · 2
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- ADvantage Therapeutics · 1 shared drug class
- AJU Pharm Co., Ltd. · 1 shared drug class
- AO GENERIUM · 1 shared drug class
- Abbott · 1 shared drug class
- AceLink Therapeutics, Inc. · 1 shared drug class
- Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
- Aciex Therapeutics, Inc. · 1 shared drug class
- 3D Medicines (Beijing) Co., Ltd. · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Sihuan Pharmaceutical Holdings Group Ltd.:
- Sihuan Pharmaceutical Holdings Group Ltd. pipeline updates — RSS
- Sihuan Pharmaceutical Holdings Group Ltd. pipeline updates — Atom
- Sihuan Pharmaceutical Holdings Group Ltd. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Sihuan Pharmaceutical Holdings Group Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sihuan-pharmaceutical-holdings-group-ltd. Accessed 2026-05-17.